glatiramer Acetate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

醋酸格拉替雷 (GA) 是一种合成氨基酸共聚物，被批准用于治疗复发缓解型多发性硬化症 (RRMS) 和临床孤立综合征 (CIS)。

Glatiramer acetate (GA) is a synthetic amino acid copolymer that is approved for treatment of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS).(In Vitro):Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels.In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days.

Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels.In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days.

——

——

Others

Other Targets

Others

——

——

147245-92-9

623.65

C25H45N5O13

>98% (HPLC)

DMSO:Insoluble;Water:10 mM

C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N

——

(-20℃)

With Ice Pack

≥ 2 years